CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...

How Australian pregnant women are tested for gestational diabetes is set to change, with new national guidelines released ...

According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

The stock market saw gains on June 20th. By noon, the Sensex had jumped 661 points, while the Nifty was up 192 points. During ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s compe ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

AstraZeneca PLC closed 22.38% below its 52-week high of £133.88, which the company achieved on September 3rd.